Filing Body
Page 1: UNITED STATES
Page 2: N/A
Page 3: PART I FINANCIAL INFORMATION
Page 4: AGILENT TECHNOLOGIES, INC.
Page 5: AGILENT TECHNOLOGIES, INC.
Page 6: AGILENT TECHNOLOGIES, INC.
Page 7: Fair Value of Financial Instruments.
Page 8: N/A
Page 9: N/A
Page 10: N/A
Page 11: N/A
Page 12: N/A
Page 13: Fair Value Hierarchy
Page 14: Impairment of Investments.
Page 15: Fair Value Hedges
Page 16: N/A
Page 17: N/A
Page 18: Components of net periodic costs.
Page 19: Contingencies
Page 20: N/A
Page 21: Description of segments.
Page 22: N/A
Page 23: N/A
Page 24: ITEM 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (UNAUD
Page 25: Critical Accounting Policies and Estimates
Page 26: Share-based compensation
Page 27: Adoption of New Pronouncements
Page 28: Operating Results
Page 29: Provision for Income Taxes
Page 30: Life Sciences
Page 31: Operating Results
Page 32: Orders and Net Revenue
Page 33: Operating Results
Page 34: Operating Results
Page 35: Income from Operations
Page 36: Net Cash Provided by/Used in Investing Activities
Page 37: Other
Page 38: ITEM 4. CONTROLS AND PROCEDURES
Page 39: Our operating results and financial condition could be harmed if the markets into which we sell our
Page 40: Failure to adjust our purchases due to changing market conditions or failure to estimate our custome
Page 41: Our business will suffer if we are not able to retain and hire key personnel.
Page 42: Our acquisitions, strategic alliances, joint ventures and divestitures may result in financial resul
Page 43: The impact of consolidation of competitors in the electronic measurement and life sciences markets i
Page 44: Our customers and we are subject to various governmental regulations, compliance with which may caus
Page 45: Third parties may claim that we are infringing their intellectual property and we could suffer signi
Page 46: We have substantial cash requirements in the United States while a majority of our cash is generated
Page 47: Our results of operations, financial condition and liquidity could be adversely affected if our long
Page 48: ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Page 49: AGILENT TECHNOLOGIES, INC.
Page 50: AGILENT TECHNOLOGIES, INC.
Exhibits
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-101.INS
EX-101.SCH
EX-101.CAL
EX-101.LAB
EX-101.PRE
EX-101.DEF
Interactive Data
XBRL Viewer